ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure
ScripThe biopharma sector saw another setback for the once-hot anti-TIGIT class on 3 April as BeiGene said it would end a Phase III trial of its antibody candidate ociperlimab (BGB-A1217) in non-small cell
ScripJiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US
Pink SheetNew US Food and Drug Administration Commissioner Martin Makary was sworn in 28 March, multiple sources told the Pink Sheet . And the timing was such that Makary was briefed on the plan to push out Ce